NCT01531972View on ClinicalTrials.gov

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Healthy
Interventions
DRUG

SEP-228432

40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days

DRUG

SEP-228432

40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days

Trial Locations (1)

06510

Molecular NeuroImaging, New Haven

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01531972 - A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects | Biotech Hunter | Biotech Hunter